- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01173900
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
The aims of this study are:
- To determine feasibility of a school-based human papillomavirus (HPV) vaccination programme in Tanzania.
- To measure the uptake and acceptability of two different vaccination strategies in rural and urban schools.
- To examine the characteristics of accepters/refusers of vaccination and to identify reasons for acceptance, refusal or non-completion.
- To measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Vaccines against human papillomavirus infection, the primary cause of cervical cancer, are an attractive cervical cancer prevention strategy for resource poor settings which lack the infrastructure for establishing and maintaining complex screening programmes.Feasibility and costs of setting up and sustaining an HPV vaccination programme will depend on whether it can be added onto an existing health programme within schools, if one exists, or whether it has to be established as a separate health intervention. Other factors will also affect vaccine coverage. For example, uptake and overall effectiveness will be critically dependent on parental and community acceptability of a vaccine that prevents a sexually transmitted infection and how the vaccine is promoted and delivered by health-care providers will influence its uptake and acceptability.
This study will determine feasibility, uptake and acceptability of different delivery strategies of school-based HPV vaccination in Tanzania, examine factors related to acceptance or refusal of vaccination and measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Three doses of quadrivalent human papillomavirus (HPV) vaccine, (Gardasil®; Merck & Co) given at 0, 2 and 6 months, will be provided to 5000 primary school girls at 134 randomly selected schools in Mwanza Region in Tanzania. Selected schools will be randomly assigned to one of two delivery strategies (age-based or class-based) and coverage and acceptability of these vaccine delivery strategies will be compared. Qualitative research will be conducted before, during and after vaccination to examine barriers to vaccination and reasons for failure to complete vaccination as well as general community perceptions. To determine factors associated with refusal a case control study will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters. The costs of introducing and scaling up HPV vaccines in schools will be estimated using established costing methods.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Mwanza, Tanzania
- National Institute for Medical Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- female pupil
- attends selected school
- born in 1998 if enrolled in school selected for age-based delivery
- attending standard (class) 6 if enrolled in school selected for class-based delivery
Exclusion Criteria:
- has not previously received HPV vaccine
- has not participated in previous HPV vaccine trials
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Class-based delivery
All girls attending standard 6 in schools selected for class-based vaccine delivery
|
0.5 ml given at 0, 2, 6 months
|
Övrig: Age-based delivery
All girls born in 1998 attending schools selected for age-based delivery
|
0.5 ml given at 0, 2, 6 months
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Vaccine coverage by delivery strategy
Tidsram: Month 12
|
Vaccine coverage will be estimated for each dose given and for those completing the full course of vaccination and compared by delivery strategy.
|
Month 12
|
Vaccine coverage (dose 2) by delivery strategy
Tidsram: Month 5
|
Month 5
|
|
Vaccine coverage (dose 1) by delivery strategy
Tidsram: Month 3
|
Month 3
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Factors associated with refusal to vaccinate or to complete vaccination course
Tidsram: Month 12
|
A case control study to determine factors associated with refusal will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters.
|
Month 12
|
Identification of barriers to HPV vaccination
Tidsram: Month 14
|
Qualitative research will be conducted to examine barriers to vaccination and reasons for failure to complete vaccination.
|
Month 14
|
Estimation of the costs of introducing and scaling up HPV vaccines in schools
Tidsram: Month 10
|
Full financial and economic costs from the provider's perspective will be collected for the intervention.
Total costs of a district vaccination programme and cost per urban school and rural school reached (if urban/rural differences are identified) and cost per fully-vaccinated girl will be estimated for the two alternative delivery strategies.
|
Month 10
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Richard J Hayes, DSC, London School of Hygiene and Tropical Medicine
- Huvudutredare: Deborah :L Watson-Jones, MD, PhD, London School of Hygiene and Tropical Medicine
- Huvudutredare: John Changalucha, BSc, National Institute for Medical Research
Publikationer och användbara länkar
Allmänna publikationer
- Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012 Nov 13;10:137. doi: 10.1186/1741-7015-10-137.
- Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjose S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis. 2012 Sep 1;206(5):678-86. doi: 10.1093/infdis/jis407. Epub 2012 Jun 18.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MITU-001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Livmoderhalscancer
-
NuVasiveAktiv, inte rekryterandeCervical Degenerative Disc DisorderFörenta staterna
-
Xin Jiang, MDOkänd
-
National Cancer Institute (NCI)AvslutadLunga | Bröst | Ovarial | Cervical | NjurFörenta staterna
-
Duke UniversityUniversity of ArkansasAvslutad
-
Taipei Veterans General Hospital, TaiwanHar inte rekryterat ännuAnnan Fusion of Spine, Cervical Region
-
Goethe UniversityAvslutadKinematik | Pålitlighet | CervicalTyskland
-
Sanliurfa Mehmet Akif Inan Education and Research...AvslutadAbort andra trimestern | Uterocervikal vinkel | Cervical Consistency IndexKalkon
-
Keimyung University Dongsan Medical CenterAvslutad
-
NuVasiveAvslutadCervical Degenerative Disc DisorderFörenta staterna
-
NuVasiveAvslutadCervical Degenerative Disc DisorderFörenta staterna
Kliniska prövningar på Gardasil® HPV vaccine
-
Partha BasuAll India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches Krebsforschungszentrum (DKFZ) och andra samarbetspartnersAktiv, inte rekryterandeLivmoderhalscancer | Cervikala precancerösa lesionerIndien
-
London School of Hygiene and Tropical MedicineMwanza Intervention Trials Unit, National Institute for Medical Research och andra samarbetspartnersAktiv, inte rekryterandeHPV-infektion | Vaccinförebyggbar sjukdomTanzania
-
University of British ColumbiaAvslutad
-
Shanghai Bovax Biotechnology Co., Ltd.Chongqing Bovax Biopharmaceutical Co., Ltd.AvslutadLivmoderhalscancer | Vulvarcancer | Vaginal cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Könsvårta | VIN 1 | VIN 2 | VIN 3 | AISKina
-
National Institute of Allergy and Infectious Diseases...National Institute of Dental and Craniofacial Research (NIDCR)AvslutadHIV-infektioner | Sexuellt överförbara sjukdomarFörenta staterna, Puerto Rico, Sydafrika, Brasilien
-
Boston Children's HospitalMerck Sharp & Dohme LLC; Harvard School of Public Health (HSPH)AvslutadInflammatorisk tarmsjukdomFörenta staterna
-
JhpiegoMerck Sharp & Dohme LLCAvslutadLivmoderhalscancerFilippinerna, Thailand
-
University Hospital, BordeauxOkändSystemisk lupus erythematosus | Transplantation | Systemisk immunsjukdomFrankrike
-
Simon DobsonMinistry of Health, British ColumbiaAvslutadLivmoderhalscancer | KönsvårtorKanada
-
Murdoch Childrens Research InstituteBrockhoff Foundation Australia; Shepherd Foundation AustraliaAvslutadLivmoderhalscancerAustralien